Analysts expect losses at Vanda, Community Health and Coherus in upcoming reports

what happened

Earnings Preview, citing LSEG data, published forecasts for three US companies. Vanda Pharmaceuticals will report results for the quarter ended September 30, 2026 on October 28. The mean estimate of five analysts points to a 23.0% revenue increase, to $69.202 million from $56.26 million a year earlier. The expected loss is 68 cents per share.

Community Health Systems also reports on October 28. Eight analysts expect revenue to fall 9.4%, to $2.797 billion from $3.09 billion a year ago, with a loss of 10 cents per share. Coherus Oncology reports on November 9. Six analysts expect revenue to rise 38.4%, to $16.011 million from $11.57 million, with a loss of 22 cents per share.

Vanda's average analyst rating is 'buy', with a median 12-month price target of $11.00 against a last close of $4.01. Community Health Systems is rated 'hold', with a $3.00 target against $2.92. Coherus is rated 'buy', with a $7.00 target against $1.01.

why it matters

These are routine pre-earnings estimates rather than news with broad market impact. The mean earnings estimates were unchanged over the past three months. The large gaps between prices and targets at Vanda and Coherus reflect low share prices rather than a separate signal. Actual quarterly results will matter more than the forecasts.

tags

instruments